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Abstract
APCs of the ocular surface, including corneal Langerhans cells (LCs), offer the opportunity to gain insight into the activity
of innate immunity. We examined corneal LCs and dry eye parameters in ankylosing spondylitis (AS). Twenty-four AS
patients with varying degrees of disease activity and 24 healthy participants were enrolled. Central and peripheral LC
numbers, and Langerhans cell morphology (LCM) were assessed with in vivo laser confocal microscopy. In addition, ocular
surface disease index, lid parallel conjunctival folds, tear break up time, and Schirmer test were evaluated. LC densities
and central LCM were greater in AS patients than in the controls. Moreover, LCM was significantly greater in patients
with higher systemic inflammation according to elevated C-reactive protein (CRP). Also, tear production was greatly
suppressed in patients with more severe onset of the systemic inflammation according to the Bath Ankylosing Spondylitis
Disease Activity Index and elevated CRP. Greater corneal LC density and LCM in AS may reflect an increased activation
state of the innate immune system of the cornea in AS, which correlates with the systemic activity of AS even without
ocular symptoms. Nonetheless, higher systemic inflammation might impair tear production, and it might partly explain
the dry eye mechanism.
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Introduction
Ankylosing spondylitis (AS) is an immune-mediated
rheumatic disease characterized by chronic inFamma-
tion. The autoimmune reaction principally aﬀects the
axial and sacroiliac joints in AS. As the disease pro-
gresses, the chronic inFammation of the spine (spondyl-
itis) causes extra bone formation and eventually leads
to the fusion of the vertebrae (ankylosis). In any stage
of the disease, systemic autoimmune reactions can
result in signiEcant target organ damage, causing per-
ipheral arthritis, enthesitis and extra-articular manifest-
ations, such as inFammation in the eye, the
gastrointestinal tract and the heart.1 The most
common inﬂammatory ophthalmic condition is uveitis,
aﬀecting 10–50% of AS patients,2–4 and Sjo¨gren’s syn-
drome (SS) can occur in 10%.5 Corneal involvement is
rare, and, to date, there is no substantial evidence on
the activity of local corneal immune system in AS. The
introduction of anti-TNF-a agents into the therapeutic
armamentarium of AS has signiﬁcantly reduced the
clinical signs and symptoms of the disease, and has
been used with success in uveitis refractory to the con-
ventional treatment regime.6 It is known from previous
studies that corneal Langerhans cells (LCs) are deeply
involved in the corneal immunoregulatory processes.
Besides being an APC of the ocular surface, they are
proposed to play a role in the inﬂammatory processes
of the ocular surface.7 Lin et al.8 have brought to light
that LCs are present in greater numbers both in SS- and
non-SS-associated dry eye. Our team has recently
demonstrated in rheumatoid arthritis (RA) patients
that LC presence was increased in the cornea and
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they were noted to be of active phenotype.9 Our objec-
tive for this present study was to further examine this
concept in another inﬂammatory rheumatic disease,
that is, AS.
Materials and methods
The study was performed in accordance with the ethical
standards set out in the 1964 Declaration of Helsinki.
Patients
Twenty-four AS patients with variable severity of dis-
ease were studied with analysis of 24 eyes (see clinical
characteristics in Table 1). AS patients were diagnosed
according to the modiﬁed New York criteria.10 All AS
patients were on a stable anti-TNF-a therapy, which
means that the duration of the same anti-TNF-a medi-
cation was more than 3 months. Fifteen out of 24 AS
patients (62%) received additional nonsteroidal anti-
inﬂammatory drugs, whilst six (25%) received sulpha-
salazin. Bath Ankylosing Spondylitis Disease Activity
Index (BASDAI) was calculated at the time of the eye
examination. BASDAI is a six-item questionnaire that
indicates the activity of the illness, and is the most
widely-used tool for the assessment of disease activity
in AS.11 At the time of evaluation of confocal micro-
scopic investigation, none of the AS patients suﬀered
any overt ocular symptom requiring speciEc ophthal-
mic assistance. Patients with diabetes; previous eye sur-
gery; uveitis within one year prior to examination;
glaucoma; congenital, mechanical or toxic injury of
the cornea; or illnesses causing corneal oedema, haze
or scars were excluded. Secondary SS was evaluated
according to the revised version of the American–
European Consensus Criteria for SS.12
Healthy volunteers comprised 24 participants who
had been free from any ocular or adnexal inﬂammation
at least one year prior to enrolment.
Examination of dry eye-related parameters
The protocols for these procedures have been described
in great detail in our previous work.9 We will summar-
ise them here in short, and in investigational order. The
Ocular Surface Disease Index (OSDI) questionnaire
was used to describe subjective eye-related discomfort.
This 12-item scale was specially designed for the
assessment of symptoms related to dry eye disease
and its eﬀect on vision.13 Lid parallel conjunctival
folds (LIPCOF) were evaluated at the temporal
aspect of the lower eyelid margin according to the
protocol speciﬁed by Pult et al.14 A Schirmer test
(ST) was carried out without anesthesia with a standar-
dized ST strip (Ref:4701001; Haag-Streit, Harlow,
UK). Wetting of the test strip represented tear produc-
tion and was considered as ST result. Patients with an
ST result of less than 5mm/5min were not automatic-
ally excluded from the study if the results of other func-
tional tests and minor salivary biopsy were normal and
no anti-Ro(SSA) or anti-La(SSB) Abs were detected.
Tear break up time (TBUT) described the interval
between the last complete blink and the ﬁrst appear-
ance of corneal black spot in seconds, and the mean
value of three consecutive measurements was inter-
preted as TBUT.
In vivo confocal cornea microscopy investigations
Image acquisition. In vivo confocal scanning laser cornea
microscopy was carried out with Heidelberg Retina
Tomograph with Rostock Cornea Module (HRTII/
RCM) (Heidelberg Engineering, Heidelberg,
Germany) on all participants after application of top-
ical anesthetic drops (Oxybuprocaine–Humacain 0.4%;
Human Pharmaceuticals, Go¨do¨llo00 , Hungary). A poly-
methyl-methacrylate cap (TomoCap; Heidelberg
Engineering) was used to cover the immersion lens of
the microscope to keep the distance from the corneal
surface stable. Carbomer gel (Vidisic; Dr Mann
Pharma, Berlin, Germany) was used as the coupling
medium to ensure airless contact between the plastic
cap and the objectives of the microscope. HRTII/
RCM uses a diode laser beam with a wavelength of
670 nm to scan the focal plane of the specimen exam-
ined. The inbuilt digital micrometre gauge ensured visu-
alization of the depth of examination ﬁeld in the
cornea. The microscope has been designed to capture
two-dimensional images with a resolution of 384 384
pixels covering an area of 400 400 mm. Forty con-
secutive images of the right cornea in each group
were taken to assess the LC density and LC morph-
ology (LCM) in a masked fashion. Images were taken







Age (years) 52.5 [34–64] 39.5 [34–52]
Gender (male/female) 19/5 21/3
AS duration (years) – 9 [7–13]




No. of patients with
history of uveitis
– 7 (29%)
CRP (mg/l) 3.2 [2.2–4.2] 12.0* [2.5–30.6]
Data are expressed as median [interquartile range].
*P< 0.05 vs healthy individuals.
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at the level of sub-basal nerve plexus (40–60 mm from
the ocular surface) to describe LC densities. LC densi-
ties were examined both at the centre and the corneal
periphery at 6 o’clock, according to the examination
scheme of Zhivov et al.15
Corneal image analysis. Five characteristic images were
selected, and the inbuilt semi-automatic system of the
device (Heidelberg Eye Explorer software, version
1.5.10.0) was used for calculating cell densities (cell
number/mm2). The mean cell number was used in the
statistics.
LCM was evaluated on a 0–3 scale, where a score of
1 represented LCs without dendrites, a score of 2 was
given to LCs with small processes, and a score of 3
represented LCs with long processes. Zero (0) depicted
the condition when the area of interest was devoid of
LCs. Each LC was scored and the mean was calculated
to describe the maturation of the LCs at both locations
of the cornea (Figure 1).
Statistical analysis
Descriptive estimates are presented as medians with
their respective interquartile ranges. Comparisons
between healthy individuals and AS patients were
made with Mann–Whitney tests. In case of comparisons
between healthy controls and AS patient subgroups,
the Kruskal–Wallis test was performed (P-values
obtained from both). Correlation analyses between
clinical variables were carried out with Spearman’s
index of linear correlation. For all tests, estimates




The results of functional assays can be seen in Table 2.
Of note, tear production was signiﬁcantly reduced, and
OSDI score was greater in AS patients than in healthy
Figure 1. Confocal microscopic image of the corneal centre (a, b) and the periphery (c, d) in the control and patient groups. Note
that the corneal centre is devoid of LCs in the control group (a), while in the periphery some non-activated and a few activated LCs
(LCM 1, 2, 3) can be seen (c). (b) Corneal centre in the patient group, where LCs are seen mainly with small processes (black arrow
indicates a score of 2 LC), while d represents LCs in the patient group with long processes (white arrowhead pointing at a score of 3
LC). The LCs in the periphery indicate the mature form of LCs in the AS group.
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individuals (P< 0.05). OSDI score was also signiﬁ-
cantly greater in patients positive for human leukocyte
antigen HLA-B27 than in controls.
Further analyses in AS subgroups showed decreased
tear production in patients with a C-reactive protein
(CRP) level of> 5mmol/l compared with patients
with a CRP level of <5mmol/l. However, there
was no diﬀerence in patients with a CRP level
of< 5mmol/l compared with controls and in patients
with a BASDAI level of >4 (P> 0.05). There was no
further diﬀerence between AS subgroups formed
according to the therapy.
Confocal microscopy
Of note, central and peripheral corneal LC density, as
well as central LCM in the AS group, were signiﬁcantly
greater than in control group (P< 0.05) (Table 3).
Further analyses in AS subgroups showed increased
LC density in both groups with low and high disease
Table 2. Dry eye-related parameters in different subgroups of AS patients.
Study group OSDI LIPCOF TBUT [s] Schirmer (mm/5min)
Healthy individuals 6.80 [4.20–12.23] 1.00 [1.00–1.00] 13.00 [11.0–14.00] 14.00 [12.00–15.00]
All AS patients 20.80* [10.40–38.59] 1.00 [1.00–1.00] 12.00 [7.50–15.00] 5.50* [1.00–15.75]
AS patients according to BASDAI score
4 (71%) 20.80* [10.40–33.71] 1.00 [0.00–1.00] 12.00 [11.0–15.00] 12.00 [1.00–17.50]
>4 (29%) 31.30* [6.25–45.50] 1.00 [1.00–2.00] 9.00 [6.00–15.00] 2.00* [1.00–7.00]
AS patients according to CRP
5 (33%) 19.78 [10.93–24.43] 0.50 [0.00–1.00] 14.00 [11.25–21.0] 16.00 [13.50–22.00]
>5 (67%) 27.07* [10.40–45.06] 1.00 [1.00–1.00] 11.00 [6.25–14.50] 1.00*, ** [1.00–5.75]
AS patients according to HLA-B27 positivity
Positive (50%) 27.00* [14.06–42.65] 1.00 [1.00–1.00] 12.00 [8.00–16.00] 9.00 [1.00–16.50]
Negative (50%) 15.60 [3.12–36.32] 1.00 [0.25–1.75] 12.00 [7.50–15.00] 4.00 [1.00–15.00]
AS patients with history of uveitis
Yes (29%) 31.30* [10.40–54.12] 1.00 [1.00–1.00] 12.00 [9.00–22.00] 13.00 [1.00–18.00]
No (71%) 20.80* [10.40–37.09] 1.00 [0.50–1.50] 12.00 [7.00–15.00] 2.00 [1.00–15.00]
Data are expressed as median [interquartile range]. Comparisons between healthy individuals and AS patients were made with Mann–Whitney tests. In
case of comparisons between healthy controls and AS patient subgroups, a Kruskal–Wallis test was performed.
*P< 0.05 vs healthy individuals; **P< 0.05 vs CRP 5.
Table 3. Confocal microscopy results in different subgroups of AS patients.
Study group LC centr. (cell/mm2) LC periph. (cell/mm2) LCM centr. LCM periph.
Healthy individuals 14.50 [0.00–35.10] 65.50 [46.75–88.00] 1.00 [0.70–1.00] 2.00 [2.00–3.00]
All AS patients 75.50* [51.18–112.6] 131.0* [80.33–168.4] 2.00* [1.00–2.00] 3.00 [2.00–3.00]
AS patients according to BASDAI score
4 (71%) 69.30* [45.70–104.0] 108.0* [78.75–137.4] 2.00* [1.00–2.00] 2.00 [2.00–3.00]
>4 (29%) 92.50* [56.50–113.0] 170.0* [135.5–204.0] 1.00 [1.00–2.00] 3.00 [3.00–3.00]
AS patients according to CRP
5 (33%) 66.15* [43.85–107.5] 136.2* [93.60–197.8] 1.50 [1.00–2.00] 2.50 [2.00–3.00]
>5 (67%) 79.25* [56.95–115.6] 121.4* [79.63–157.2] 2.00* [1.00–2.00] 3.00 [2.00–3.00]
AS patients according to HLA-B27 positivity
Positive (50%) 75.50* [59.48–107.9] 140.5* [88.95–197.8] 2.00* [1.00–2.00] 3.00 [2.00–3.00]
Negative (50%) 74.65* [43.85–117.7] 98.40* [79.63–136.6] 1.50* [1.00–2.00] 2.50 [2.00–3.00]
AS patients with history of uveitis
Yes (29%) 111.2* [72.00–129.7] 143.3* [109.8–204.0] 2.00* [2.00–2.00] 3.00 [2.00–3.00]
No (71%) 60.30* [34.65–91.75] 108.0* [79.75–153.9] 1.00* [1.00–2.00] 3.00 [2.00–3.00]
Data are expressed as median [interquartile range]. Comparisons between healthy individuals and AS patients were made with Mann–Whitney tests. In
case of comparisons between healthy controls and AS patient subgroups, a Kruskal–Wallis test was performed.
*P< 0.05 vs healthy individuals.
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activity, as assessed by the BASDAI index and the
serum CRP levels. Correlation analysis showed a
strong positive correlation between BASDAI and per-
ipheral LC density (r¼ 0.51, P< 0.05). The activation
status of the LCs, as assessed by the central corneal
LCM score, increased in patients with CRP levels
>5mmol/l compared with controls and patients with
CRP levels <5mmol/l. We found no further diﬀerence
between AS subgroups formed according to the
therapy.
Discussion
Confocal microscopy, which is capable of visualizing
the ultrastructure of the organ examined at a cellular
level, has been developed in recent years. Through
obtaining coronal optical sections of the transparent
part of the eye, we can explore the resident innate
immune system of the ocular surface. Under non-
pathological circumstances, the majority of LCs reside
in the periphery of the cornea, with numbers of LCs
tapering rapidly towards the corneal centre.15 Upon
diﬀerent stimuli, LCs are capable of transforming into
an active participant of corneal immune responses char-
acterized by the formation of dendrite-like processes.16
LCs have been shown to play important roles in pro-
moting inﬂammatory reactions and immunogenity, and
have a pivotal role in the regulation of ocular surface
immune processes.17
To the best of our knowledge, this is the Erst study to
investigate the characteristics of corneal LC density and
morphology in AS.We conﬁned our investigation on the
density and morphology of corneal LCs to their pre-
sumed role in ocular surface diseases and their extraor-
dinary capacity to stimulate naive T-cells. We have
demonstrated increased density and activation of den-
dritic cells in the cornea of AS patients in the absence of
clinically manifest ocular inFammation. These novel
results support the systemic multi-organ-related feature
of AS aﬀecting the eye and are also in line with the
results of Wakamatsu18,19 and Villani,20 who found
greater inﬂammatory cell inﬁltration of the conjunctiva
in SS and in atopic keratoconjunctivitis. It has been
demonstrated that the inﬂammatory cells, and structural
changes of the cornea and activation of keratocytes
could highlight corneal involvement in local or general
conditions.21 Similarly to our recent study on RA
patients,9 we observed an increase in the number and
activation of central LCs, which did not appear to be
associated with articular inFammatory disease activity;
however, the central corneal LCM score was increased
in patients with a higher systemic inﬂammation accord-
ing to the CRP level, and the peripheral LC density
showed positive correlation with BASDAI, which fur-
ther supports our theory on the corneal inﬂuence of AS.
We have further demonstrated that a history of uve-
itis resulted in abundance of LCs in the cornea. These
LCs expressed no protrusions, suggesting their
immunological inactivity. Whether these inactive LCs
enhance the tolerogenic wing of innate immune system
by producing anti-inﬂammatory factors to regain the
integrity and function of ocular surface is still
unknown. The connection between the LC presence
and ocular surface disturbances is still controversial
and requires further studies in this ﬁeld.
HLA-B27 is the primary disease susceptibility gene
for AS, which occurs in 6–10% of Caucasians, but is
present in more than 90% of patients with AS and 50%
of patients with acute anterior uveitis.22 Their function
is not fully understood, but they are the cellular mar-
kers of individuality and they play an important role in
immunological reactivity at the cellular level. The fact
that AS is a heterogeneous disease has been recognized
for the past 30 years from the diﬀerences betweenHLA-
B27-positive and HLA-B27-negative patients.23 The
aim of this study was not only to investigate the corneal
manifestation in AS, but also to clarify the possible role
of HLA-B27 status in corneal immunologic reactivity.
The prevalence of HLA-B27 in the overall AS patient
group in our clinic is more than 90%, which is in
accordance with data in literature.22 In a second step,
we selected a 1:1 ratio pf HLA-B27-positive to
HLA-B27-negative patients. Laval et al.24 showed
greater frequency of relapse, severity and complications
of uveitis in HLA-B27-positive patients compared with
those ofHLA-B27-negative patients. Surprisingly, there
was no signiﬁcant diﬀerence in selected HLA-B27-posi-
tive and HLA-B27-negative patients neither in clinical
characteristics nor in dry eye-related parameters and
confocal microscopic data. However, the number of
investigated AS patients is limited; our data suggest
that the HLA-B27 status has no inﬂuence on corneal
immune mechanism.
Therapy-related alterations in tear production and
their presumed role on LCs were demonstrated in
recent work by our team.9 We noted decreased tear
production in patients with elevated CRP, representing
an active systemic inﬂammatory status in AS. This
observation was conﬁrmed in our preliminary analysis,
where the relationship between these parameters had a
statistically signiﬁcant strong positive correlation. Our
data are in accordance with the results of Villani
et al.,25 which suggest that these alterations of the
cornea are rather associated with the systemic inﬂam-
matory eﬀect of the disease than a speciﬁc pathogenic
diﬀerences in dry eye disease. Theoretically, with higher
systemic inﬂammation in AS, one may assume an
increase in the secretion of pro-inﬂammatory cytokines
in the tears. Presumably, the higher amount of these
cytokines in the tears of AS patients might impair
tear production, and it may partly explain the dry eye
mechanism without the presence of true overlapping
SS. In fact, IL-1, IL-6 and TNF-a have been found to
be overexpressed and to be accumulated in the ocular
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surface in dry eye,26–28 and they have a key role in the
pathomechanism of AS.29 In turn, these cytokines are
thought to have the capacity to decrease tear produc-
tion via neuronal and hormonal eﬀects,28 and have
been shown to facilitate centripetal migration of
LCs.30 Our theory can be partly supported by Villani
et al.,31 who showed a higher IL-1a and IL-6 level in
active RA patients with secondary SS, and found lower
levels of those cytokines in patients with a reduction of
the systemic inﬂammation; however, the number of
investigated patients was limited and they could not
prove this pattern in their non-Sjo¨gren RA patient
group.31 The limitation of our study is that only anti-
TNF-a-treated AS patients were involved.
Investigation of anti-TNF-a-naive AS patients to see
whether the systemic anti-inﬂammatory drug has an
inﬂuence on the corneal immune mechanisms would
also be interesting. Despite the anti-TNF-a therapy,
seven of the 24 AS patients (29%) were refractory to
the ﬁrst anti-TNF-a agent and three out of these seven
AS patients were already treated with the third anti-
TNF-a agent. Therefore, this anti-TNF-a non-respon-
der AS group represented a group of patients with par-
ticularly high systemic inﬂammation.
As previous studies demonstrated the heterogeneity
of resident corneal immune cells,32 we can rather con-
sider the cornea as an active participant in the complex-
ity of interactions between environment and the ocular
surface then a non-compliant anatomical surface.9
Indeed, the immune privilege is secured through a
series of active mechanisms rather than a simple conse-
quence of the avascular and alymphatic nature of the
cornea. Additionally, our results support the role of the
systemic inﬂammation in dry eye patomechanism.
Further investigations are required to clarify the
role of adaptive immunity in the cornea in systemic
inﬂammatory rheumatic diseases, and the connection
between the dry eye mechanism, the systemic inﬂam-
mation and the LCs. Maintenance of corneal homeo-
stasis relies on complex interactions of various
immunomechanisms, where ocular surface LCs might
play a key role.
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